The WFH Humanitarian Aid Program, is leading the effort to change the lack of access to care in developing countries by providing consistent and predictable access to donated factor and other treatment products, as well as education and other support. In Cambodia, donated factor helped stabilize the condition of a 14-year-old boy with moderate hemophilia A, giving him a second chance at life.
The boy was admitted to the National Pediatric Hospital in Phnom Penh. He was in serious condition: he had scoliosis of the thoracic-lumbar region of his spine that had led to a bedsore lesion in his buttock. In addition to this, the boy’s right hip was dislocated and he had avascular necrosis. His bedsore wound had been there for some time, exacerbated by lack of proper treatment and lack of access to factor. His condition was serious enough that doctors feared for his life. At the National Pediatric Hospital, the boy quickly received donated factor replacement therapy, and donated emicizumab—both provided by the WFH Humanitarian Aid Program. This treatment saved his life, and although his condition is serious, doctors are working hard to stabilize him.
The WFH Humanitarian Aid Program has donated nearly 6.5 million IUs of factor to Cambodia since 2015, with 2 million IUs of factor going to the country in 2020 alone. In addition to factor, the Program donated 37,800 mg of emicizumab to Cambodia in 2020.
To find out more about the WFH Humanitarian Aid Program, please click here.
About the WFH Humanitarian Aid Program
The WFH Humanitarian Aid Program improves the lack of access to care and treatment by providing much-needed support for people with inherited bleeding disorders in developing countries. By providing patients with a more predictable and sustainable flow of humanitarian aid donations, the WFH Humanitarian Aid Program makes it possible for patients to receive consistent and reliable access to treatment and care. None of this would be possible without the generous support of Sanofi Genzyme and Sobi, our Founding Visionary Contributors; Bayer and Roche, our Visionary Contributors; Grifols, our Leadership Contributor; and our Contributors, CSL Behring and Takeda. To learn more about the WFH Humanitarian Aid Program, visit www.treatmentforall.org.